Business
Allied Corp. One Step Closer to First Commercial Harvest With Psychoactive Strain Evaluation Approval
Allied Corp. One Step Closer to First Commercial Harvest With Psychoactive Strain Evaluation Approval.
About this update from Allied Corp.
[{"type":"text","content":"\n KELOWNA, British Columbia, May 05, 2020 (GLOBE NEWSWIRE) -- Allied Corp. (\"Allied\" or the \"Company\") (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce that on April 29, 2020 the Ministry of Justice in Colombia signed a resolution authorizing Allied Corp.’s wholly owned subsidiary, Medicolombia’s Cannabis S.A.S. (\"Medicolombias\") to evaluate the Company’s proprietary strains in order to select the best pheno-typed psychoactive cannabis strains with the best commercial production characteristics. This comes as a significant milestone for the company on its path to the first commercial harvest. Along with the previous approval for non-psychoactive evaluation, Medicolombias can now evaluate all of Allied’s psychoactive and non-psychoactive strains that were registered in 2019. This authorization allows Allied to evaluate the 10 different proprietary strains in a controlled environment in order to select the best pheno-typed strains that are best suited for quality and production efficiency. Allied expects to continue to follow its production plan in order to move towards the first commercial harvest in or around Q3 2020. “With this approval, Allied is one step closer to our first commercial harvest. Even amid the COVID delays with logistics, travel and isolation, the production team has continued to achieve significant milestones for the company. This speaks to the strength and perseverance of the team,” said Calum Hughes, CEO of Allied. For more information on Allied Corp., visit www.allied.health           About Allied Corp.Allied Corp. is an international medical cannabis production company with a mission to address today’s medical issues by researching, creating and producing targeted cannabinoid health solutions. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products. Investor Relations:[email protected] Forward-Looking Statements: This press release contains “forward-looking informatio...